

a genus Agenus Inc.

Subsidiaries: Antigenics, Inc., Aronex Pharmaceuticals, Inc.

Locations: Massachusetts (HQ)

Industries: Pharmaceuticals Biotechnology and Life Sciences

RISK LEVEL:



Medium Risk

DESCRIPTION:

Agenus, Inc. is Medium Risk. The company often yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. The company occasionally embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues at times. This approach fails to safeguard free exercise, free speech, and free enterprise.

Corporate Weaponization

Has canceled customers, suppliers, or vendors due to their political views or religious beliefs OR Medium Risk corporately boycotts, divests, or sanctions regions, people groups, or industries.

Agenus integrates ESG into its business practices. From its 2023 ESG Charter: "Agenus will be integrating an ESG management platform that will enable the Company to gather relevant information, conduct reviews, and help establish ESG priorities" and the company "seek[s] to integrate [its] ESG priorities on a global scale" (1). The company promotes divisive sex and gender policies. Its Code of Conduct requires international vendors to include sexual orientation and gender identity in their nondiscrimination policy (2). However, the company has not canceled customers, suppliers, or vendors based on political views or religious beliefs (3).

Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.

N/A

Agenus does not publish charitable giving guidelines (1).

Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.

High Risk

Agenus appears to prioritize diversity over merit in its leadership composition. From its Guidelines on Significant Corporate Governance Issues: "The Governance Committee is committed to ensuring that the individuals on the Board of Directors represent a mix of backgrounds and experiences that will maximize the Board of Director's ability to serve the Company's needs and the long-term interests of Agenus and its stockholders" (1). The company does not provide viewpoint protections for its employees (2).

Corporate Governance and Public Policy

Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.	High Risk
--	------------------

Agenus supports DEI within its business practices. From its 2023 ESG Charter: "We ensure all employees are treated fairly and equally and promote diversity, equality, and inclusion (DEI)" ([1](#)). The company supports ESG within its business practices. From its 2023 ESG Charter: "Our governance framework and culture provide the basis for proactive engagement and shared accountability of ESG across our operations, including research and development, clinical trials, manufacturing and all other aspects of the business" ([2](#)). The company hosted a workshop on employee members sharing their diversity and inclusion experiences ([3](#)).

Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.	Lower Risk
---	-------------------

Agenus has not used corporate funds to advance ideological causes, organizations, or policies ([1](#)).

Uses corporate political actions and/or financial contributions for ideological, non-business purposes.	N/A
--	------------

Agenus does not operate a PAC or report on its lobbying at this time ([1](#))[\(2\)](#)[\(3\)](#).

The contents of this website and related resources (collectively, the "materials") are general in nature and intended for educational use only. Nothing in the materials or any other 1792 Exchange content constitutes legal or professional advice for any specific matter. Anyone seeking legal or professional advice should obtain such advice from competent counsel. Since individual circumstances vary, anyone reviewing the materials and/or any other 1792 Exchange content is strongly urged to obtain specific legal and/or other professional advice before acting or refraining from acting based on such materials or other 1792 Exchange content. 1792 Exchange accepts no responsibility for any loss or damage, howsoever incurred, which may result from accessing or relying on the materials or any other 1792 Exchange content. Further, 1792 Exchange disclaims, to the fullest extent permitted by law, all liability for any acts or omissions based on the materials or any other 1792 Exchange content.

USER AGREEMENT: Company reports and other resources are intended only for the private educational use of the registered user. Republishing and distributing reports and resources is strictly prohibited. By downloading reports and resources, the user accepts these conditions.

© 1792 Exchange 2023